245:
Thereby pharmaceutical companies could realize high returns and firm valuations. Companies like CVS and
Express Scripts in the US have begun implementing pricing based on indication and in countries like Italy, similar forms of pricing are already being used. For example, Express Scripts' "Oncology Care Value Program," uses indication-based pricing for certain oncology medications and was launched in 2016. Italy on the other hand, uses a model similar to indication-based pricing where the amount the hospital pays for certain drugs varies based on what it's used for. Patients can receive reimbursements for treatments based on their response and either be fully or partially refunded. Italy's reimbursement system is run by AIFA, the Italian Medicines Agency, which is the national authority that regulates drugs in Italy. In contrast, Germany and France use weighted-average pricing - a pricing system that calculates a single price based on the average volume and value of all approved indications. Using weighted-average pricing effectively reduces cancer drugs' list prices as new indications are approved. England, Scotland, and Canada use another form of indirect indication-based pricing: differential discounts on single list prices for each indication. Furthermore, European countries were shown to restric coverage to supplemental low-value indications using clinical coverage restrictions or financial coverage restrictions, such as managed entry agreements.
60:. Indications are included in the Indications and Usage section of the Prescribing Information. The primary role of this section of labeling is to enable health care practitioners to readily identify appropriate therapies for patients by clearly communicating the drug's approved indication(s). The Indications and Usage section states the disease or condition, or manifestation or symptoms thereof, for which the drug is approved, as well as whether the drug is indicated for the treatment, prevention, mitigation, cure, relief, or diagnosis of that disease or condition. Additionally, the Indications and Usage section should contain the approved age groups as well as other information necessary to describe appropriate use (e.g., identifying the indicated patient/disease subgroups, stating if adjunctive therapy is required).
74:
216:
if it is found that there is substantial evidence that benefits of treatment outweigh the risks, the proposed labeling in the
Prescribing Information is appropriate, and the manufacturing process is safe and adequate, then the drug is approved to go to market under that now FDA-approved indication. Even after approval, the FDA CDER continues to do postmarking surveillance of the drug through
236:, also known as indication specific pricing or indication value-based pricing. Since drugs can be used for different indications, this form of pricing would set different prices for each indication based on the value the drug offers for whatever it is being used to treat. This pricing scheme is often discussed in relation to
253:
There has been some thought on incorporating the indication in prescription drug labeling as an approach to improve patient understanding of the medications they are on. This information can help healthcare providers reduce medication errors related to drugs that may look and sound alike. Knowing the
244:
Currently, most medications in the United States are priced the same regardless of what they're being used for or how effective they are at improving outcomes. Concerns were therefore raised that patients and insurers may be paying too high prices for indications with a relatively low clinical value.
280:
of conditions (such as diseases) that the test is expected to achieve. Additional factors that influence a decision whether a medical test should be performed or not include: cost of the test, time taken for the test or other practical or administrative aspects. The possible benefits of a diagnostic
257:
However, there are still some challenges with incorporating the indication of use on prescription drug labels. Revealing the indication of use on prescription drug labels can breach patient confidentiality since the label will disclose private information publicly. Some medications can also be used
215:
or a
Biologics License Application (BLA) for approval to the FDA's Center for Drug Evaluation and Research (CDER) and the proposed scientific evidence for use in an intended population is evaluated by a team of physicians, statisticians, chemists, pharmacologists, and other scientists. Essentially,
205:
The purpose for adding FDA-approved indications in the United States is to ensure that healthcare providers can easily identify appropriate use of drug therapy. Gaining FDA approval is based on the body of scientific evidence supporting the effectiveness of a drug treatment. The scientific evidence
192:
Off-label indications are drugs that are used for medical indications that have not been approved by the FDA. Off label indications often have some clinical significance to back the use, but they have not gone through the extensive testing required by the FDA to have an official labeled indication.
240:
drugs, which are costly. Oncology drugs can be used for multiple different types of cancers so by applying indication-specific pricing, the drug would be priced based on how effective it is for treating each type of cancer. If the drug is more effective for Cancer A than Cancer B, then the patient
175:
for the indication and manufacturers are allowed to market their drug for the indication. A drug can have more than one FDA labeled indication, which means that it can be used for multiple medical conditions. As the evidence and consensus for use of the drug increases and strengthens, its class of
591:
258:
for multiple diseases and one disease may have multiple medications for its prevention or treatment, therefore adding an indication on prescription labels in these cases may cause some confusion and may not be able to actually fit onto the label.
1006:
Michaeli DT, Michaeli T (December 2022). "Overall
Survival, Progression-Free Survival, and Tumor Response Benefit Supporting Initial US Food and Drug Administration Approval and Indication Extension of New Cancer Drugs, 2003-2021".
922:
Michaeli DT, Michaeli T (December 2022). "Overall
Survival, Progression-Free Survival, and Tumor Response Benefit Supporting Initial US Food and Drug Administration Approval and Indication Extension of New Cancer Drugs, 2003-2021".
748:
210:
process: discovery and development, pre-clinical research (testing safety), and clinical research (testing efficacy). After there is adequate completion of research and development phases by the drug companies, they send a
683:
1241:
45:
is a valid reason to use a certain test, medication, procedure, or surgery. There can be multiple indications to use a procedure or medication. An indication can commonly be confused with the term
1156:
745:
254:
indication of the drug can also help providers determine if the dose of the drug is appropriate per indication, and this can greatly improve patient safety and drug effectiveness.
1323:
675:
713:
281:
test may also be weighed against the costs of unnecessary tests and resulting unnecessary follow-up and possibly even unnecessary treatment of incidental findings.
1233:
127:
Most countries and jurisdictions have a licensing body whose duty is to determine whether to approve a drug for a specific indication, based on the relative
272:
Each test has its own indications and contraindications, but in a simplified fashion, how much a test is indicated for an individual depends largely on its
49:. A diagnosis is the assessment that a particular medical condition is present while an indication is a reason for use. The opposite of an indication is a
794:
367:
530:
1347:
971:
Michaeli DT, Michaeli T (July 2023). "Cancer Drug Prices in the United States: Efficacy, Innovation, Clinical Trial
Evidence, and Epidemiology".
1148:
501:
84:
650:
338:
746:
Indication-specific pricing of pharmaceuticals in the United States health care system: a report from the 2015 ICER Membership Policy Summit
136:
620:
580:
559:
241:
taking the drug to treat Cancer A will pay more than the person using it for Cancer B because they are getting more value out of it.
1295:
705:
1270:
388:
826:"Value and Price of Multi-indication Cancer Drugs in the USA, Germany, France, England, Canada, Australia, and Scotland"
330:
471:
114:
875:"Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA"
581:"Indications and Usage Section of Labeling for Human Prescription Drug and Biological Products — Content and Format"
180:" or "primary" while others are called "second line", "third line" etc. A drug may be indicated as an "adjunct" or "
297:
53:, a reason to withhold a certain medical treatment because the risks of treatment clearly outweigh the benefits.
1378:"Rapid magnetic resonance imaging vs radiographs for patients with low back pain: a randomized controlled trial"
766:
277:
221:
359:
522:
1422:
1355:
267:
171:
Medication that have label indications mean that they were approved by the FDA. This means that they are
31:
96:
194:
148:
144:
17:
642:
493:
467:
1052:"Valuation and Returns of Drug Development Companies: Lessons for Bioentrepreneurs and Investors"
135:
for the particular use. In the United States, indications for medications are regulated by the
92:
1376:
Jarvik JG, Hollingworth W, Martin B, Emerson SS, Gray DT, Overman S, et al. (June 2003).
1184:
Flume M, Bardou M, Capri S, Sola-Morales O, Cunningham D, Levin LA, Touchot N (January 2016).
612:
172:
212:
551:
8:
1234:"SafeGuardRx Improves Affordability and Access to Budget-Busting Drugs | Express Scripts"
233:
1210:
1185:
1125:
1100:
1076:
1051:
1032:
948:
899:
874:
850:
825:
440:
415:
176:
indication is improved. Preferred drugs (and other treatments) are also referred to a "
1186:"Feasibility and attractiveness of indication value-based pricing in key EU countries"
1399:
1315:
1296:"Incorporating Indications into Medication Ordering--Time to Enter the Age of Reason"
1215:
1130:
1081:
1036:
1024:
988:
952:
940:
904:
855:
786:
445:
46:
1389:
1307:
1205:
1197:
1120:
1112:
1071:
1063:
1016:
980:
932:
894:
886:
845:
837:
778:
435:
427:
416:"Medication-indication knowledge bases: a systematic review and critical appraisal"
207:
181:
50:
752:
1262:
248:
1116:
1067:
984:
890:
841:
152:
140:
392:
276:
for that individual, which largely depends on the absolute difference between
1416:
1394:
1377:
463:
56:
In the United States, indications for prescription drugs are approved by the
782:
163:
In the United States there are label indications and off-label indications.
1403:
1319:
1219:
1201:
1134:
1085:
1028:
992:
944:
908:
859:
790:
449:
431:
1311:
1149:"Indication-Specific Drug Pricing – Simple in Theory, Complex in Reality"
1020:
936:
193:
Drug companies can not provide any official medication information (e.g.
301:
873:
Michaeli DT, Mills M, Michaeli T, Miracolo A, Kanavos P (August 2022).
966:
964:
962:
360:"What's the Value of the Drug Indication? | Clinical Drug Information"
389:"Contraindication - Medical Definition and More from Merriam-Webster"
331:"Indications for Drugs: Approved vs. Non-approved by MedicineNet.com"
27:
Valid reason to use a certain test, medication, procedure, or surgery
959:
703:
673:
640:
237:
217:
38:
1263:"The Italian Medicines Agency | AIFA Agenzia Italiana del Farmaco"
151:) holds this responsibility for centrally authorized drugs in the
1099:
Michaeli DT, Yagmur HB, Achmadeev T, Michaeli T (November 2022).
755:. Boston: Institute for Clinical and Economic Review, March 2016.
177:
1375:
1098:
1049:
298:"Indication - Medical Definition and More from Merriam-Webster"
1050:
Michaeli DT, Yagmur HB, Achmadeev T, Michaeli T (March 2022).
158:
872:
249:
Incorporating indication of use on prescription drug labeling
1183:
414:
Salmasian H, Tran TH, Chase HS, Friedman C (November 2015).
1293:
413:
232:
Indications can impact the pricing of medications through
57:
1101:"Value drivers of development stage biopharma companies"
420:
Journal of the
American Medical Informatics Association
823:
706:"Surveillance - Postmarketing Surveillance Programs"
1294:Schiff GD, Seoane-Vazquez E, Wright A (July 2016).
824:Michaeli DT, Mills M, Kanavos P (September 2022).
1414:
1005:
970:
921:
1056:Therapeutic Innovation & Regulatory Science
767:"Indication-Specific Pricing for Cancer Drugs"
143:under the phrase "Indications and Usage". The
81:The examples and perspective in this section
1369:
1190:Journal of Market Access & Health Policy
643:"Development & Approval Process (Drugs)"
1348:"The Case for Indications on Prescriptions"
407:
159:Label indications vs. off-label indications
830:Applied Health Economics and Health Policy
222:FDA Adverse Event Reporting System (FAERS)
99:, or create a new section, as appropriate.
1393:
1209:
1124:
1075:
898:
849:
704:Center for Drug Evaluation and Research.
674:Center for Drug Evaluation and Research.
641:Center for Drug Evaluation and Research.
439:
227:
115:Learn how and when to remove this message
1105:The European Journal of Health Economics
206:is gathered in the first 3 steps in the
14:
1415:
740:
738:
736:
734:
732:
730:
669:
667:
1342:
1340:
1289:
1287:
1179:
1177:
1175:
1173:
819:
817:
815:
813:
811:
744:Pearson SD, Dreitlein B, Henshall C.
764:
325:
323:
321:
319:
67:
1300:The New England Journal of Medicine
727:
664:
24:
1337:
1284:
1170:
808:
474:from the original on 16 April 2013
25:
1434:
316:
523:"NCI Dictionary of Cancer Terms"
261:
72:
1326:from the original on 2020-08-01
1273:from the original on 2018-11-15
1255:
1244:from the original on 2018-11-19
1226:
1159:from the original on 2018-11-09
1141:
1092:
1043:
999:
915:
866:
797:from the original on 2023-09-01
758:
716:from the original on 2018-09-08
697:
686:from the original on 2018-09-08
653:from the original on 2019-04-22
634:
623:from the original on 2019-04-23
605:
594:from the original on 2023-11-24
573:
562:from the original on 2016-04-19
533:from the original on 2018-01-23
504:from the original on 2019-04-02
370:from the original on 2018-11-21
341:from the original on 2018-02-25
200:
184:", added to a first line drug.
139:(FDA), and are included in the
613:"The Drug Development Process"
544:
515:
486:
456:
381:
352:
290:
278:pre- and post-test probability
13:
1:
464:"Off-Label Use - MeSH Result"
284:
197:) for off label indications.
1009:Journal of Clinical Oncology
925:Journal of Clinical Oncology
676:"New Drug Application (NDA)"
268:Indications of medical tests
137:Food and Drug Administration
7:
95:, discuss the issue on the
32:Indication (disambiguation)
10:
1439:
1117:10.1007/s10198-021-01427-5
1068:10.1007/s43441-021-00364-y
985:10.1016/j.jval.2023.06.020
891:10.1007/s10637-022-01227-5
842:10.1007/s40258-022-00737-w
265:
213:New Drug Application (NDA)
29:
1267:www.agenziafarmaco.gov.it
879:Investigational New Drugs
527:National Cancer Institute
145:European Medicines Agency
1395:10.1001/jama.289.21.2810
468:Medical Subject Headings
364:www.wolterskluwercdi.com
63:
1238:lab.express-scripts.com
783:10.1001/jama.2014.13235
765:Bach, Peter B. (2014).
1202:10.3402/jmahp.v4.30970
228:Effect on drug pricing
173:clinically significant
1153:Managed Care magazine
498:TheFreeDictionary.com
266:Further information:
1312:10.1056/nejmp1603964
1021:10.1200/JCO.22.00535
937:10.1200/JCO.22.00535
432:10.1093/jamia/ocv129
131:of the drug and its
93:improve this section
83:may not represent a
30:For other uses, see
1423:Medical terminology
556:The Free Dictionary
234:Value-based Pricing
751:2020-08-16 at the
494:"second-line drug"
167:Label indications:
1388:(21): 2810–2818.
1015:(35): 4095–4106.
979:(11): 1590–1600.
931:(35): 4095–4106.
777:(16): 1629–1630.
395:on 3 October 2011
125:
124:
117:
16:(Redirected from
1430:
1408:
1407:
1397:
1373:
1367:
1366:
1364:
1363:
1354:. Archived from
1344:
1335:
1334:
1332:
1331:
1291:
1282:
1281:
1279:
1278:
1259:
1253:
1252:
1250:
1249:
1230:
1224:
1223:
1213:
1181:
1168:
1167:
1165:
1164:
1145:
1139:
1138:
1128:
1111:(8): 1287–1296.
1096:
1090:
1089:
1079:
1047:
1041:
1040:
1003:
997:
996:
968:
957:
956:
919:
913:
912:
902:
870:
864:
863:
853:
821:
806:
805:
803:
802:
762:
756:
742:
725:
724:
722:
721:
701:
695:
694:
692:
691:
671:
662:
661:
659:
658:
638:
632:
631:
629:
628:
609:
603:
602:
600:
599:
585:
577:
571:
570:
568:
567:
548:
542:
541:
539:
538:
519:
513:
512:
510:
509:
490:
484:
483:
481:
479:
460:
454:
453:
443:
426:(6): 1261–1270.
411:
405:
404:
402:
400:
391:. Archived from
385:
379:
378:
376:
375:
356:
350:
349:
347:
346:
327:
314:
313:
311:
309:
300:. Archived from
294:
208:drug development
120:
113:
109:
106:
100:
76:
75:
68:
51:contraindication
21:
1438:
1437:
1433:
1432:
1431:
1429:
1428:
1427:
1413:
1412:
1411:
1374:
1370:
1361:
1359:
1346:
1345:
1338:
1329:
1327:
1292:
1285:
1276:
1274:
1261:
1260:
1256:
1247:
1245:
1232:
1231:
1227:
1182:
1171:
1162:
1160:
1147:
1146:
1142:
1097:
1093:
1048:
1044:
1004:
1000:
973:Value in Health
969:
960:
920:
916:
871:
867:
822:
809:
800:
798:
763:
759:
753:Wayback Machine
743:
728:
719:
717:
702:
698:
689:
687:
672:
665:
656:
654:
639:
635:
626:
624:
611:
610:
606:
597:
595:
583:
579:
578:
574:
565:
563:
550:
549:
545:
536:
534:
521:
520:
516:
507:
505:
492:
491:
487:
477:
475:
462:
461:
457:
412:
408:
398:
396:
387:
386:
382:
373:
371:
358:
357:
353:
344:
342:
329:
328:
317:
307:
305:
304:on 14 July 2011
296:
295:
291:
287:
270:
264:
251:
230:
203:
195:package inserts
161:
121:
110:
104:
101:
90:
77:
73:
66:
35:
28:
23:
22:
15:
12:
11:
5:
1436:
1426:
1425:
1410:
1409:
1368:
1336:
1306:(4): 306–309.
1283:
1254:
1225:
1169:
1155:. 2018-05-06.
1140:
1091:
1062:(2): 313–322.
1042:
998:
958:
914:
885:(4): 798–809.
865:
836:(5): 757–768.
807:
757:
726:
696:
663:
633:
604:
572:
543:
514:
485:
455:
406:
380:
351:
315:
288:
286:
283:
263:
260:
250:
247:
229:
226:
202:
199:
160:
157:
153:European Union
141:package insert
123:
122:
87:of the subject
85:worldwide view
80:
78:
71:
65:
62:
26:
9:
6:
4:
3:
2:
1435:
1424:
1421:
1420:
1418:
1405:
1401:
1396:
1391:
1387:
1383:
1379:
1372:
1358:on 2018-11-09
1357:
1353:
1349:
1343:
1341:
1325:
1321:
1317:
1313:
1309:
1305:
1301:
1297:
1290:
1288:
1272:
1268:
1264:
1258:
1243:
1239:
1235:
1229:
1221:
1217:
1212:
1207:
1203:
1199:
1195:
1191:
1187:
1180:
1178:
1176:
1174:
1158:
1154:
1150:
1144:
1136:
1132:
1127:
1122:
1118:
1114:
1110:
1106:
1102:
1095:
1087:
1083:
1078:
1073:
1069:
1065:
1061:
1057:
1053:
1046:
1038:
1034:
1030:
1026:
1022:
1018:
1014:
1010:
1002:
994:
990:
986:
982:
978:
974:
967:
965:
963:
954:
950:
946:
942:
938:
934:
930:
926:
918:
910:
906:
901:
896:
892:
888:
884:
880:
876:
869:
861:
857:
852:
847:
843:
839:
835:
831:
827:
820:
818:
816:
814:
812:
796:
792:
788:
784:
780:
776:
772:
768:
761:
754:
750:
747:
741:
739:
737:
735:
733:
731:
715:
711:
707:
700:
685:
681:
677:
670:
668:
652:
648:
644:
637:
622:
618:
614:
608:
593:
589:
582:
576:
561:
557:
553:
547:
532:
528:
524:
518:
503:
499:
495:
489:
473:
469:
465:
459:
451:
447:
442:
437:
433:
429:
425:
421:
417:
410:
394:
390:
384:
369:
365:
361:
355:
340:
336:
332:
326:
324:
322:
320:
303:
299:
293:
289:
282:
279:
275:
269:
262:Medical tests
259:
255:
246:
242:
239:
235:
225:
223:
219:
214:
209:
198:
196:
190:
189:
185:
183:
179:
174:
169:
168:
164:
156:
154:
150:
146:
142:
138:
134:
130:
119:
116:
108:
105:November 2017
98:
94:
88:
86:
79:
70:
69:
61:
59:
54:
52:
48:
44:
40:
33:
19:
1385:
1381:
1371:
1360:. Retrieved
1356:the original
1351:
1328:. Retrieved
1303:
1299:
1275:. Retrieved
1266:
1257:
1246:. Retrieved
1237:
1228:
1196:(1): 30970.
1193:
1189:
1161:. Retrieved
1152:
1143:
1108:
1104:
1094:
1059:
1055:
1045:
1012:
1008:
1001:
976:
972:
928:
924:
917:
882:
878:
868:
833:
829:
799:. Retrieved
774:
770:
760:
718:. Retrieved
709:
699:
688:. Retrieved
679:
655:. Retrieved
646:
636:
625:. Retrieved
616:
607:
596:. Retrieved
587:
575:
564:. Retrieved
555:
546:
535:. Retrieved
526:
517:
506:. Retrieved
497:
488:
476:. Retrieved
458:
423:
419:
409:
397:. Retrieved
393:the original
383:
372:. Retrieved
363:
354:
343:. Retrieved
334:
306:. Retrieved
302:the original
292:
273:
271:
256:
252:
243:
231:
204:
201:FDA approval
191:
187:
186:
170:
166:
165:
162:
132:
128:
126:
111:
102:
82:
55:
42:
36:
1352:Drug Topics
710:www.fda.gov
680:www.fda.gov
647:www.fda.gov
617:www.fda.gov
478:14 December
399:14 December
335:MedicineNet
308:14 December
274:net benefit
1362:2018-11-02
1330:2019-09-26
1277:2018-11-21
1248:2018-11-21
1163:2018-11-02
801:2023-09-01
720:2018-11-02
690:2018-11-02
657:2018-11-02
627:2018-11-17
598:2018-11-01
566:2016-04-20
537:2016-04-20
508:2016-04-20
374:2018-10-15
345:2018-11-01
285:References
188:Off-label:
178:first line
43:indication
1037:251317641
953:251317641
552:"adjunct"
97:talk page
47:diagnosis
18:Indicated
1417:Category
1404:12783911
1324:Archived
1320:27464201
1271:Archived
1242:Archived
1220:27226845
1157:Archived
1135:35038054
1086:35018622
1029:35921606
993:37516196
945:35921606
909:35389145
860:35821360
795:Archived
791:25279433
749:Archived
714:Archived
684:Archived
651:Archived
621:Archived
592:Archived
560:Archived
531:Archived
502:Archived
472:Archived
450:26335981
368:Archived
339:Archived
238:oncology
218:MedWatch
182:adjuvant
133:efficacy
91:You may
39:medicine
1211:4864834
1126:9550717
1077:8854317
900:9288371
851:9385843
588:fda.gov
441:5009909
1402:
1318:
1218:
1208:
1133:
1123:
1084:
1074:
1035:
1027:
991:
951:
943:
907:
897:
858:
848:
789:
448:
438:
129:safety
1033:S2CID
949:S2CID
584:(PDF)
64:Drugs
41:, an
1400:PMID
1382:JAMA
1316:PMID
1216:PMID
1131:PMID
1082:PMID
1025:PMID
989:PMID
941:PMID
905:PMID
856:PMID
787:PMID
771:JAMA
480:2010
446:PMID
401:2010
310:2010
220:and
1390:doi
1386:289
1308:doi
1304:375
1206:PMC
1198:doi
1121:PMC
1113:doi
1072:PMC
1064:doi
1017:doi
981:doi
933:doi
895:PMC
887:doi
846:PMC
838:doi
779:doi
775:312
436:PMC
428:doi
149:EMA
58:FDA
37:In
1419::
1398:.
1384:.
1380:.
1350:.
1339:^
1322:.
1314:.
1302:.
1298:.
1286:^
1269:.
1265:.
1240:.
1236:.
1214:.
1204:.
1192:.
1188:.
1172:^
1151:.
1129:.
1119:.
1109:23
1107:.
1103:.
1080:.
1070:.
1060:56
1058:.
1054:.
1031:.
1023:.
1013:40
1011:.
987:.
977:26
975:.
961:^
947:.
939:.
929:40
927:.
903:.
893:.
883:40
881:.
877:.
854:.
844:.
834:20
832:.
828:.
810:^
793:.
785:.
773:.
769:.
729:^
712:.
708:.
682:.
678:.
666:^
649:.
645:.
619:.
615:.
590:.
586:.
558:.
554:.
529:.
525:.
500:.
496:.
470:.
466:.
444:.
434:.
424:22
422:.
418:.
366:.
362:.
337:.
333:.
318:^
224:.
155:.
1406:.
1392::
1365:.
1333:.
1310::
1280:.
1251:.
1222:.
1200::
1194:4
1166:.
1137:.
1115::
1088:.
1066::
1039:.
1019::
995:.
983::
955:.
935::
911:.
889::
862:.
840::
804:.
781::
723:.
693:.
660:.
630:.
601:.
569:.
540:.
511:.
482:.
452:.
430::
403:.
377:.
348:.
312:.
147:(
118:)
112:(
107:)
103:(
89:.
34:.
20:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.